Stockscreener 앱 받기
14.03
1.23%
-0.21
전일 마감가:
$14.24
열려 있는:
$14.26
하루 거래량:
65,160
Relative Volume:
0.35
시가총액:
$953.15M
수익:
$-9,000
순이익/손실:
$-68.03M
주가수익비율:
-13.36
EPS:
-1.05
순현금흐름:
$-44.76M
1주 성능:
+4.26%
1개월 성능:
-2.33%
6개월 성능:
-10.81%
1년 성능:
-20.31%
1일 변동 폭
$13.99
$14.50
1주일 범위
$13.41
$14.75
52주 변동 폭
$12.56
$25.00
펄스 바이오 Stock (PLSE) Company Profile
명칭
Pulse Biosciences Inc
전화
510-906-4600
주소
3957 POINT EDEN WAY, HAYWARD, CA
PLSE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
14.06 | 965.01M | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
553.94 | 192.25B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
200.25 | 57.34B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
79.20 | 38.71B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
253.22 | 36.82B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
WST
West Pharmaceutical Services Inc
|
269.76 | 19.25B | 2.96B | 487.70M | 344.00M | 6.6758 |
펄스 바이오 Stock (PLSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-07 | 개시 | Oppenheimer | Outperform |
| 2021-07-27 | 개시 | Stephens | Overweight |
| 2021-03-11 | 개시 | Maxim Group | Buy |
| 2021-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-12 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 개시 | H.C. Wainwright | Buy |
모두보기
펄스 바이오 주식(PLSE)의 최신 뉴스
How (PLSE) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Pulse Biosciences holds 2025 annual stockholder meeting - MSN
Pulse Biosciences (NASDAQ:PLSE) Trading Up 5%Here's What Happened - MarketBeat
Pulse Biosciences drops 38% after InvestingPro’s "Overvalued" warning By Investing.com - Investing.com Australia
Pulse Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor - sharewise.com
Pulse Biosciences and MD Anderson to study nPulse for thyroid cancer - Yahoo
Pulse Biosciences, Inc. Announces Research Collaboration with MD Anderson - TradingView — Track All Markets
Pulse Biosciences, MD Anderson, launch study of novel ablation technology for thyroid cancer - Medical Economics
Pulse Biosciences to evaluate PFA in treating thyroid cancer - MassDevice
Pulse Biosciences (PLSE) Collaborates with MD Anderson for Thyro - GuruFocus
Pulse Biosciences to begin thyroid cancer treatment study in 2026 - Investing.com
Pulse Biosciences to begin thyroid cancer treatment study in 2026 By Investing.com - Investing.com South Africa
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology - Business Wire
With 73% ownership, insiders at Pulse Biosciences, Inc. (NASDAQ:PLSE) are pretty optimistic and have been buying recently - Yahoo Finance
Is Pulse Biosciences Inc. stock a buy before product launchesDollar Strength & AI Enhanced Trading Alerts - Newser
Bull Run: Is Pulse Biosciences Inc stock near bottom after declineJuly 2025 Retail & Stock Portfolio Risk Management - BỘ NỘI VỤ
How cyclical is Pulse Biosciences Inc. (6L8) stock compared to rivalsRecession Risk & Weekly High Return Forecasts - Newser
Is Pulse Biosciences Inc. stock a safe investment in uncertain markets2025 Institutional Moves & Real-Time Volume Analysis - Newser
Trading Systems Reacting to (PLSE) Volatility - news.stocktradersdaily.com
Is Pulse Biosciences Inc. stock a defensive play in 2025Trade Volume Report & Safe Entry Zone Identification - Newser
Is Pulse Biosciences Inc. stock near bottom after declineDay Trade & Reliable Breakout Stock Forecasts - Newser
Will Pulse Biosciences Inc. (6L8) stock benefit from Fed rate cutsVolume Spike & Community Trade Idea Sharing - Newser
PLSE: Nanosecond PFA enables disruptive, non-thermal ablation with rapid clinical and commercial expansion - TradingView — Track All Markets
How dovish Fed policy supports Pulse Biosciences Inc. (6L8) stockJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Pulse Biosciences (PLSE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Will Pulse Biosciences Inc. (6L8) stock benefit from mergersJuly 2025 Selloffs & Consistent Income Trade Ideas - Newser
Value Recap: Can Pulse Biosciences Inc. stock beat market expectations this quarter - moha.gov.vn
Operating cash flow per share of Pulse Biosciences, Inc. – SWB:6L8 - TradingView
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 21, 2025 - BioSpace
How Pulse Biosciences Inc (PLSE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Is Pulse Biosciences Inc. (6L8) stock in buy zone after pullbackJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com
Is Pulse Biosciences Inc. stock supported by innovation pipelineJuly 2025 Reactions & Real-Time Stock Movement Alerts - newser.com
Will Pulse Biosciences Inc. stock maintain momentum in 20252025 Performance Recap & Real-Time Volume Analysis - newser.com
Top chart patterns to watch in Pulse Biosciences Inc.July 2025 Price Swings & High Conviction Trade Alerts - newser.com
How high can Pulse Biosciences Inc. stock goJuly 2025 Macro Moves & Weekly High Return Opportunities - newser.com
What recovery options are there for Pulse Biosciences Inc.Entry Point & Free AI Powered Buy and Sell Recommendations - newser.com
Can Pulse Biosciences Inc. (6L8) stock resist broad market declinesWatch List & Growth Focused Entry Point Reports - newser.com
Why hedge funds are buying Pulse Biosciences Inc. stockJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
Will Pulse Biosciences Inc. (6L8) stock draw ESG focused fundsTrend Reversal & Daily Volume Surge Signals - newser.com
Why Pulse Biosciences Inc. (6L8) stock benefits from AI revolutionEarnings Risk Report & Risk Managed Investment Entry Signals - newser.com
펄스 바이오 (PLSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
펄스 바이오 주식 (PLSE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Oct 02 '25 |
Sale |
18.53 |
4,600 |
85,238 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Option Exercise |
1.53 |
400 |
612 |
43,698 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Sale |
18.49 |
20,000 |
369,800 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Sale |
18.48 |
400 |
7,392 |
43,298 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Option Exercise |
4.00 |
181,534 |
726,136 |
284,406 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Option Exercise |
4.00 |
25,000 |
100,000 |
147,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Sale |
16.28 |
25,000 |
407,000 |
122,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Sale |
16.21 |
20,000 |
324,200 |
122,872 |
1.75%
0.16%
자본화:
|
볼륨(24시간):